Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
about
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaLoss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibitionPLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.p63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase ItchGeroconversion: irreversible step to cellular senescencePolo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaksB-cell lymphoma 6 promotes proliferation and survival of trophoblastic cellsImpact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.Hair curvature: a natural dialectic and review.Less understood issues: p21(Cip1) in mitosis and its therapeutic potential.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.Molecular insight into the regulation and function of MCAK.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Clinical Development of Anti-mitotic Drugs in Cancer.The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma.
P2860
Q33820876-F36C097D-947C-454A-BBA7-4A2C14D1D295Q35740037-39E38DFF-6FE4-4F02-913C-80F2EF0508C0Q35832219-294037B3-15DC-4A79-AB98-07CA716108C1Q36183728-B9CF6BAB-D868-42C6-A62E-CAAA6F5584CEQ36186369-8033F2C9-DD1C-46A8-9686-D4FCC76485AEQ36771791-0ABDF467-582D-4A54-9FEC-549A3852B6A3Q36839342-A46E29D1-E7D8-42A7-AC47-6879CB2CDA4EQ37708943-1CA7C2CE-626F-4421-A0EF-0D0ED9E47D93Q38195115-B1A67B5E-ED9F-4DA6-B61A-D37C38B1ED00Q38214413-5CD1682E-A21D-4F9E-BF0F-C35B1392EBEDQ38252591-CA7E15EF-7E44-47E3-A771-8DAD839B3879Q38310745-A3F84950-379A-4FB0-9F25-2D5334DEE177Q38824242-F8D8C3BB-7E22-4B99-8FD2-2912E8D2535BQ38825915-173A4F16-BD49-4311-B222-EEDF16A5AA89Q38959358-BB01662B-7D4B-4627-A328-1A89A28D29F0Q39363642-A0DC91CA-42A5-474F-AABD-32EB5866E49FQ41694208-C5C7C05C-9987-416A-8AF7-D2CCD83E1186Q47142820-C3780203-AD97-4A64-B542-EABB55DEE831Q50296864-7E84F12F-8A26-49F2-A21E-368D61488267Q53210669-A4EF8702-E4AB-4C9E-97F5-005520287CC8
P2860
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Battle of the eternal rivals: ...... ke kinase 1 as cancer therapy.
@en
type
label
Battle of the eternal rivals: ...... ke kinase 1 as cancer therapy.
@en
prefLabel
Battle of the eternal rivals: ...... ke kinase 1 as cancer therapy.
@en
P2860
P921
P356
P1433
P1476
Battle of the eternal rivals: ...... ke kinase 1 as cancer therapy.
@en
P2093
Frank Louwen
Juping Yuan
P2860
P304
P356
10.18632/ONCOTARGET.1096
P407
P5008
P577
2013-07-01T00:00:00Z